[go: up one dir, main page]

TN2010000105A1 - Derives d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du recepteur d'histamine -3 - Google Patents

Derives d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du recepteur d'histamine -3

Info

Publication number
TN2010000105A1
TN2010000105A1 TNP2010000105A TN2010000105A TN2010000105A1 TN 2010000105 A1 TN2010000105 A1 TN 2010000105A1 TN P2010000105 A TNP2010000105 A TN P2010000105A TN 2010000105 A TN2010000105 A TN 2010000105A TN 2010000105 A1 TN2010000105 A1 TN 2010000105A1
Authority
TN
Tunisia
Prior art keywords
isoquinolinyl
receptor antagonists
histamine receptor
isoindolinyl
derivatives
Prior art date
Application number
TNP2010000105A
Other languages
English (en)
Inventor
Jonathan Laird Gross
Albert Jean Robichaud
Dahui Zhou
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of TN2010000105A1 publication Critical patent/TN2010000105A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention propose un composé de formule I et son utilisation pour le traitement d'un trouble du système nerveux central en rapport avec ou influencé par le recepteur d'histamine -3.
TNP2010000105A 2007-09-12 2010-03-05 Derives d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du recepteur d'histamine -3 TN2010000105A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99363607P 2007-09-12 2007-09-12
PCT/US2008/075981 WO2009036144A1 (fr) 2007-09-12 2008-09-11 Dérivés d'isoquinolinyle et d'isoindolinyle convenant comme antagonistes de l'histamine-3

Publications (1)

Publication Number Publication Date
TN2010000105A1 true TN2010000105A1 (fr) 2011-09-26

Family

ID=40261509

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2010000105A TN2010000105A1 (fr) 2007-09-12 2010-03-05 Derives d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du recepteur d'histamine -3

Country Status (25)

Country Link
US (1) US20090069300A1 (fr)
EP (1) EP2200989A1 (fr)
JP (1) JP2010539180A (fr)
KR (1) KR20100054856A (fr)
CN (1) CN101848896A (fr)
AP (1) AP2010005202A0 (fr)
AR (1) AR068423A1 (fr)
AU (1) AU2008298926A1 (fr)
BR (1) BRPI0817061A2 (fr)
CA (1) CA2699384A1 (fr)
CL (1) CL2008002726A1 (fr)
CO (1) CO6300955A2 (fr)
CR (1) CR11303A (fr)
DO (1) DOP2010000079A (fr)
EA (1) EA201000316A1 (fr)
EC (1) ECSP10010025A (fr)
MA (1) MA31699B1 (fr)
MX (1) MX2010002760A (fr)
NI (1) NI201000036A (fr)
PA (1) PA8795701A1 (fr)
PE (1) PE20090651A1 (fr)
TN (1) TN2010000105A1 (fr)
TW (1) TW200927114A (fr)
WO (1) WO2009036144A1 (fr)
ZA (1) ZA201001751B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
GB0907284D0 (en) 2009-04-28 2009-06-10 Queen Mary & Westfield College Compounds for inducing cellular apoptosis
WO2011014462A1 (fr) 2009-07-27 2011-02-03 Gilead Palo Alto, Inc. Composés hétérocycliques condensés en tant que modulateurs de canaux ioniques
US8703759B2 (en) 2010-07-02 2014-04-22 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
EP2632461A4 (fr) * 2010-10-29 2014-04-02 Merck Sharp & Dohme Composés d'isoindolinone utiles comme inhibiteurs de pde 10
CN103649056B (zh) * 2011-05-10 2016-04-27 吉利德科学公司 作为离子通道调节剂的稠合杂环化合物
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (fr) 2011-07-01 2018-04-28
US9173395B2 (en) 2011-07-04 2015-11-03 Bayer Intellectual Property Gmbh Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants
WO2013076590A1 (fr) 2011-11-23 2013-05-30 Oxygen Healthcare Research Pvt. Ltd Composés benzothiazines en tant que ligands de récepteur h3
CN105254554B (zh) * 2014-07-14 2018-01-30 南开大学 一种制备异吲哚啉酮类化合物的方法
US20230167093A1 (en) * 2020-04-08 2023-06-01 Remix Therapeutics Inc. Compounds and methods for modulating splicing
JP2023540270A (ja) 2020-08-28 2023-09-22 カムクワット バイオサイエンシーズ インコーポレイテッド 複素環式化合物およびその使用
CN115819347B (zh) * 2022-11-14 2024-08-30 暨明医药科技（苏州）有限公司 一种1-烷基-3-溴吡唑的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933829A (en) * 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
US4166853A (en) * 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
ATE253359T1 (de) * 1997-05-01 2003-11-15 Lilly Co Eli Antithrombotische mittel
CA2441080A1 (fr) 2001-03-23 2002-10-03 Eli Lilly And Company Composes d'aryl alkylamines non imidazole comme antagonistes des recepteurs h3 de l'histamine, preparation et applications therapeutiques
NZ538459A (en) * 2002-09-19 2008-04-30 Lilly Co Eli Diaryl ethers as opioid receptor antagonist
CA2565411C (fr) * 2004-05-14 2010-04-20 Millennium Pharmaceuticals, Inc. Composes et procedes pour l'inhibition de progression mitotique
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
EP1848696A1 (fr) * 2005-01-21 2007-10-31 Schering Corporation Derives d'imidazole et de benzimidazole utiles en tant qu'antagonistes de l'histamine h3
WO2006113140A2 (fr) * 2005-04-15 2006-10-26 Elan Pharmaceuticals, Inc. Nouveaux composes s'utilisant dans l'antagonisme du recepteur de bradykinine b1

Also Published As

Publication number Publication date
TW200927114A (en) 2009-07-01
PE20090651A1 (es) 2009-05-28
ECSP10010025A (es) 2010-08-31
PA8795701A1 (es) 2009-04-23
CN101848896A (zh) 2010-09-29
ZA201001751B (en) 2010-11-24
MX2010002760A (es) 2010-04-01
AR068423A1 (es) 2009-11-18
KR20100054856A (ko) 2010-05-25
AP2010005202A0 (en) 2010-04-30
CL2008002726A1 (es) 2008-10-10
EP2200989A1 (fr) 2010-06-30
US20090069300A1 (en) 2009-03-12
JP2010539180A (ja) 2010-12-16
CO6300955A2 (es) 2011-07-21
CR11303A (es) 2010-03-18
MA31699B1 (fr) 2010-09-01
CA2699384A1 (fr) 2009-03-19
EA201000316A1 (ru) 2010-10-29
DOP2010000079A (es) 2010-03-31
BRPI0817061A2 (pt) 2015-03-24
NI201000036A (es) 2010-08-13
WO2009036144A1 (fr) 2009-03-19
AU2008298926A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
TN2010000105A1 (fr) Derives d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du recepteur d'histamine -3
TN2010000107A1 (fr) Derives d'azacyclylisoquinolinone et isoindolinone servant d'antagonistes du recepteur d'histamine -3
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
WO2007136668A3 (fr) N-benzoyle et n-benzylpyrrolidin-3-ylamines comme antagonistes de l'histamine-3
TN2009000324A1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides
MY155212A (en) Quaternary ammonium salt compounds
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
TW200720266A (en) Benzodioxane and benzodioxolan derivatives and uses thereof
TW200718692A (en) Dihydrobenzofuran derivatives and uses thereof
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
WO2008056259A3 (fr) Dérivés d'oxazole utilisés en tant que modulateurs allostériques positifs des récepteurs métabotropiques du glutamate
UA106873C2 (uk) Сполуки заміщених діазепанів як антагоністи орексинових рецепторів
EA200900635A1 (ru) Антагонисты прогестеронового рецептора
WO2007142905A3 (fr) Dérivés de 1-sulfonylindazolylamine et de 1-sulfonylindazolylamide en tant que ligands de la 5-hydroxytryptamine-6
MA33559B1 (fr) Composes bicycliques 5,6- heteroaryle contenant l'uree comme inhibiteurs de kinase.
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
MA31910B1 (fr) Antagonistes des recepteurs non steroidiens des mineralocorticoides derives de la 6h-dibenzo[b,e]oxepine
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
ATE486058T1 (de) Prolinamidderivate als nk3-antagonisten
NO20080165L (no) Alfa-(aryl-OR heteroaryl-metyl)-beta piperidinopropanamidforbindelser som ORL1-receptorantagonister
TN2015000490A1 (fr) Dérivés d'imidazo-triazine servant d' inhibiteurs de pde10
ATE468118T1 (de) Bis-1,2,3,4-tetrahydroisochinolinderivate und ihre verwendung als pharmazeutika
DE602006010540D1 (de) (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl)-amine mit aktivität am 5-ht-rezeptor